Qiming Venture Partners USA

Qiming Venture Partners USA, launched in 2017, focuses on early-stage investments in healthcare, particularly therapeutics and healthcare technologies, across the U.S. and Europe. Backed by its China-based parent firm Qiming Venture Partners, the U.S. arm leverages both financial and human capital to support transformative innovations in healthcare, including drug development and digital health solutions. With over $550 million raised across three funds, Qiming USA has already invested in more than 30 companies and achieved notable exits through M&A and IPOs. Their strategy is centered on partnering with visionary healthcare entrepreneurs, offering not just capital but also deep technical expertise and a global network, including synergies with the broader Qiming platform in China. Key team members include managing partners like Mark McDade and the recent addition of Isaac Ciechanover, whose extensive background in biotech strengthens Qiming’s healthcare focus. Their third fund, closed at $260 million in 2022, continues to invest in innovative therapeutics and health tech ventures that have the potential to make a significant impact on patient outcomes​.